$7.50

I am expecting CT news next week!

CT = Clinical Trial

Hope it is good news...

What you need to know about clinical trials:

https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf

Pay attention to last paragraph at bottom of page 7: "...2. OBJECTIVE RESPONSE RATE"

Will buy more CLRB after the 2017 Marcum MicroCap Conference on Thursday, June 15 at 11:00 AM ET

When CLRB DOES ITS STANDARD POST CONFERENCE SWOON.

LOL

I have the "buy low" part figured out with this stock!

If you know it in advance

Bloody leakers! SPECIAL COUNSEL SHOULD PROSECUTE THEM!

TWO MORE WEEKS UNTIL

some clinical trial news-WILL IT BE ON COHORT FOUR OF CLINICAL TRIAL ONE, OR ON PHASE TWO TRIALS JUST STARTED? I AM GUESSING IT WIILL BE THE FORMER WITH A REVISED UPWARD "ORR" ABOVE 27%!

BUT WHO KNOWS?

AT THIS POINT IN TIME, ONLY A LEAKER WOULD KNOW AND IN THE STOCK MARKET THERE ARE LEAKERS EVERWHERE AND THEY TRADE IN SIZE- IN VOLUME! ;))

WATCH FOR A HIGH VOLUME DAY COMING UP WITH OVER A MILLION SHARES TRADED. PRICE WILL TELL YOU IF THE NEWS IS GOOD OR BAD FROM THE LEAKERS!

Phase 2 has been "initiated" for CLR131 for MM and

Other blood cancers.

https://www.smarteranalyst.com/2017/03/30/stock-update-nasdaqclrb-cellectar-biosciences-inc-initiates-nci-supported-phase-ii-trial-clr-131-multiple-myeloma-blood-cancers/

I would be careful not to defame even a corporation without clear and convincing evidence that you can document and cross check.

March 2017:

“I would like to thank the entire team at Cellectar whose diligent efforts enabled the company to initiate the Phase II trial a full quarter ahead of our original guidance. The prospect of extending patient survival with a one or two-dose treatment continues to drive a high sense of urgency for all involved in this study as we continue to focus on providing clinical benefit to patients who suffer from these difficult to treat conditions,” said Jim Caruso, president and CEO of Cellectar Biosciences. “Given the results from our Phase I trial of CLR 131 in multiple myeloma, we are enthusiastic about the potential outcomes of this Phase II trial, and look forward to reporting results as they become available.”

Good catch, friend. 27% is good, but

Not great. Maybe the ratio improves over time?

Snakers: where did you get 27% ORR?

https://www.biooncology.com/clinical-trials/efficacy-endpoints.html

I read that over 20% is a good sign for shareholders of any clinical trial drug stock and its patients, of course.

ORR IN GENERAL:

ORR
ORR is the portion of patients with a tumor size reduction of a predefined amount for a minimum time period. Response duration is measured from the time of initial response until documented tumor progression.

The FDA has generally defined ORR as the sum of partial responses (PRs) and CRs. When defined in this manner, ORR is a direct measure of the drug's antitumor activity. Stable disease is not included in the ORR. Stable disease is optimally evaluated in randomized trials examining TTP or PFS. Stable disease may reflect, in part, the natural history of the disease rather than being entirely attributed to the drug's therapeutic effect.

Several response criteria have been considered appropriate to evaluate antitumor response. The selected response criteria to be used in registration trials should be prospectively discussed with the FDA. When comparing ORRs in different arms, the number of PRs and CRs, response durations, locations of responses, and associations between responses and symptom improvement should be examined. The clinical significance of the ORR should be assessed by the magnitude and duration in a risk-benefit analysis.

Yes, HUGH, and no one gets it!

OVER 19 MONTHS AND GROWING MEDIAN OVERALL SURVIVAL


CEO: "...We continue to see consistently impressive safety results and positive indications of efficacy, including the most significant clinical outcome overall survival. In fact, I am pleased to report that Cohort 1 evaluable patients have now achieved median overall survival of 19.3 months and the survival benefit continues to increase for these patients as well as all evaluable patients enrolled in our Phase 1 trial.

CLRB CEO 5-11-17:

"...We continue to see consistently impressive safety results and positive indications of efficacy, including the most significant clinical outcome overall survival. In fact, I am pleased to report that Cohort 1 evaluable patients have now achieved median overall survival of 19.3 months and the survival benefit continues to increase for these patients as well as all evaluable patients enrolled in our Phase 1 trial..." from transcript!

This seems RANDOM

But is it? $1.86 pps...

He is happy with 10,000 options

@$1.74 pps?

That says something from the inside ...

THANKS FOR THE PROMPT LINKS!

An EMP over Hawaii or California

Would change the price here to the Ultra Positive.

BUT WHAT ARE THE ODDS OF GETTING PAST AN INTERCEPTOR MISSILE FROM VANDENBERG? 50/50?

YEAH, A BANKROLL!

I missed another cheap bottom to buy more CLRB.

But in my defense, I own too much already!!!

?? Lol

THERE IS GOOD NEWS COMING AND IT IS STARTING TO LEAK!

Nice price action today

Wonder what's going on.

ONE BIG BLOCK BUY AFTER LUNCH?

Taking profits "SOON"...such as they are...

The daily charting and trading is getting old...and with North Korea acting up in the face of a second US NAVY Aircraft Carrier Task force off shore, I am thinking: "There will be a chance of a lifetime to exit UVXY..."JUST A HUNCH THAT WHEN Trump returns from his religion and rockets tour- the second Korean war begins within weeks. 20 million dead? Pure horror to stop madman horror?

EFFECTIVE DIVERSION TOO...THE FAKE NEWS IS OVERWHELMING THE ADMINSTRATION IN THE EXECUTIVE BRANCH IN D.C. FWIW, The Revenge of the Deep State! Millions dead in Korea....

Oncology Clinical Trial "end points":

WE NEED TO KNOW THESE CONCEPTS ESPECIALLY ORR, AND ORR NEEDS TO BE ABOVE THIRTY PERCENT RANGE TO MAKE EVERYONE HAPPY, IINCLUDING THE PATIENTS!:

https://www.biooncology.com/clinical-trials/efficacy-endpoints.html


WATCHING AND WAITING for big news SOON on Phase one trial COHORT four and LATE IN JUNE A news release on phase two clinical trial. TIME FLIES! ALL ABOARD!!

SURE IS QUIET here!

The day is near when there will be dozens of new screen names posting HERE!

Might be time to leverage with CLRB Warrants,

Clrbz...?

Agree..and Good Morning to you!

Yes, assuming is a dangerous and expensive business. DD is the only acceptable basis for profitable assumptions.

My DD reveals Phase 1 COHORT 4 news will be out before the end of May and it should be very good news.
Phase 2 clinical trial initial news should be released by the last of June and it should be good news on CLR 131 from what has been happening with P1 COHORT 4!

I have un-named sources at the New Your Times and Washington Post for all of this...leaked information.
TRUMP THAT, lol

Your patient will be tested exiting

Above $5 pps: am I exiting too early?

WHERE'S THE TOP FOR CLRB AFTER CLR 131 WAS PROVEN SUCCESSFUL?$7.50 pps? $17.50?


Now those are the frustrating decisions!

after waiting all this time, WHY SHOULD I SELL OUT TOO LOW?

frustrating!!!

Summary of Q1 and Q2 2017 Accomplishments to Date:
Positive safety, tolerability and activity data through Cohort 3 of Phase 1 study of CLR 131 in multiple myeloma
Initiation of fourth cohort of Phase 1 study of CLR 131 in multiple myeloma
Initiation of NCI-supported Phase 2 clinical trial of CLR 131 in multiple myeloma and other hematologic malignancies
Consolidation of intellectual property portfolio for CLR 131 in multiple myeloma following license agreement with Wisconsin Alumni Research Foundation
Publication in Nature Reviews Clinical Oncology and presentation at Academic Surgical Congress, both regarding PDC platform
Additional intellectual property protection for CLR 131 in solid tumors in the US
Grant of US patent for CLR 124 in PET imaging
Additional US method of use patents for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog for the detection of multiple cancer types
Japanese composition of matter patent for CLR 1501 and CLR 1502
Additional Japanese method of use patents granted for CLR 131 and CLR 125 in cancer stem cells
Appointment of John Friend as chief medical officer
Appointment of Doug Swirsky and Fred Driscoll to the Cellectar Board of Directors
“We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences. “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.”

HAPPY DAYS COMING IN JUNE

WE WILL PARTY LIKE ITS JUNE 2016 again!

buy low, like now and sell high like July?!

$2.00 pps I FEEL BETTER!

I Feel good!

$3.00 IN JUNE IS NEXT AND HOW WE GET THERE WILL BE A SURPRISE-A PLESANT SURPRISE!

??yes, lol me too.. always happens: big D

AO: I wil vote as board recommends

Just this time...activist investor needs to be next!

I think this June wil be like last June,

Trading at a price over $3 pps. Exit plans are sooo important!

I WONDER WHAT THE FAIR BUY OUT PRICE IS FOR CLRB IN MAY 2017?

Need a plan here folks...On May 11th conference call they may disclose buyout interest?... joint venture?

May 11th conference call news?

https://finance.yahoo.com/news/cellectar-biosciences-host-conference-call-123000181.html

If I were them, I would release a PR on the 10th about COHORT 4, Phase 1

Vanguard Group owns CLRB

http://www.nasdaq.com/symbol/clrb/ownership-summary

THANKS FOR THE NASDAQ LINK!

Interesting they bought after their professional DD...!!!



http://www.nasdaq.com/symbol/clrb/ownership-summary see #5

No specified date, I believ,

They might be released as early as end of summer, IMHO.

ORR data cannot be rushed, it comes out as PATIENTS live on or die. We can only humbly stand and wait, like John Milton recommended.

"...THEY ASLO SERVE WHO ONLY STAND AND WAIT....."

They short positive news,

Thinking mice don't prove much to average investors.

WAIT UNTIL THEE Phase 1 COHORT 4 NEWS IS RELEASED AND THEN THE PHASE 2 INITIAL NEWS WITH ORR NUMBERS IS RELEASED- SHORTS WILL CUT AND RUN FOREVER!!!

SEC filing: DILUTION of 1,200,000 outstanding common shares,

...But the authorized number of shares doubles: To 80 million.

We need very good news soon, or else....

http://ih.advfn.com/p.php?pid=nmona&article=74417651&symbol=CLRB

80,000 shares of CLRB for CFO/CPA:

https://www.linkedin.com/in/chad-kolean-bbbb3148

http://www.bloomberg.com/research/stocks/people/person.asp?personId=140835126&privcapId=37613299

Wish that I had a $200,00+ compensation package...

What has he done to earn them?

200,000 shares for conference presentations and supervising a dozen or two employees?

Hiring a medical VIP?

DILUTION.

Price Creeping up today...

This level seems like a secure bottom. But your really significant $5 news is likely a couple of months away-

i.e. Phase 2 news update or COHORT 4 Phase 1 news update.

Good luck to all LONGS!

Crushing shorts preview on minor news,

Imagine what major news will do to those holding CLRB DOWN!

https://finance.yahoo.com/quote/clrb?ltr=1

Time to crush the short positions in CLRB,

and time to load the truck for CLRB LONGS.

AS I RECALL THE GOAL IS TO BUY LOW AND SELL HIGH!

THINGS ARE LOOKING UP! eom